Key points are not available for this paper at this time.
The angiogenic capability of PGE2 was tested by implanting pellets of an ethylene vinyl acetate slow release polymer containing PGE2 on the chorioallantoic membrane of 8-day-old chicken embryos. Elvax pellets releasing approximately 0.2, 2.0, or 20 ng/day PGE2 were found to induce neovascular responses. In contrast, pellets releasing 2.0 or 20 ng/day of either PGA2, PGF2, or TXB2 did not appear to be angiogenic when compared with PGE2. These release rates of PGE2 are similar to those reported for a variety of tumors, activated macrophages, inflammatory exudates, and rheumatoid synovia, suggesting that PGE2 may be a key factor in various neovascular reactions.
Form et al. (Tue,) studied this question.